vs
Side-by-side financial comparison of ASP Isotopes Inc. (ASPI) and FIBROGEN INC (KYNB). Click either name above to swap in a different company.
FIBROGEN INC is the larger business by last-quarter revenue ($25.4M vs $16.7M, roughly 1.5× ASP Isotopes Inc.). On growth, ASP Isotopes Inc. posted the faster year-over-year revenue change (1295.7% vs -29.9%). ASP Isotopes Inc. produced more free cash flow last quarter ($-47.4M vs $-59.3M).
ASP Isotopes Inc.ASPIEarnings & Financial Report
ASP Isotopes Inc. is a specialty materials firm focused on developing and producing high-purity custom isotopes. Its products serve key sectors including nuclear medicine, targeted cancer therapies, advanced energy, and industrial research, with customers across North America, Europe and Asia Pacific.
FibroGen Inc. is a biopharmaceutical firm developing and commercializing innovative therapies for unmet medical needs, targeting fibrotic diseases, anemia and cancer. Its lead product roxadustat is approved in multiple markets including China and Japan, serving patients across key therapeutic segments.
ASPI vs KYNB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2024
| Metric | | |
|---|---|---|
| Revenue | $16.7M | $25.4M |
| Net Profit | — | $-32.9M |
| Gross Margin | 12.5% | 15.9% |
| Operating Margin | — | -193.9% |
| Net Margin | — | -129.8% |
| Revenue YoY | 1295.7% | -29.9% |
| Net Profit YoY | -586.8% | 57.1% |
| EPS (diluted) | — | $-0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.7M | — | ||
| Q3 25 | $4.9M | — | ||
| Q1 24 | — | $25.4M | ||
| Q4 23 | — | $-73.8M | ||
| Q3 23 | — | $40.1M | ||
| Q2 23 | — | $44.3M | ||
| Q1 23 | — | $36.2M | ||
| Q4 22 | — | $34.4M |
| Q4 25 | — | — | ||
| Q3 25 | $-12.9M | — | ||
| Q1 24 | — | $-32.9M | ||
| Q4 23 | — | $-56.2M | ||
| Q3 23 | — | $-63.6M | ||
| Q2 23 | — | $-87.7M | ||
| Q1 23 | — | $-76.7M | ||
| Q4 22 | — | $-66.2M |
| Q4 25 | 12.5% | — | ||
| Q3 25 | 8.7% | — | ||
| Q1 24 | — | 15.9% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | 89.4% | ||
| Q2 23 | — | 87.1% | ||
| Q1 23 | — | 90.3% | ||
| Q4 22 | — | 85.7% |
| Q4 25 | — | — | ||
| Q3 25 | -306.1% | — | ||
| Q1 24 | — | -193.9% | ||
| Q4 23 | — | 128.8% | ||
| Q3 23 | — | -158.2% | ||
| Q2 23 | — | -198.7% | ||
| Q1 23 | — | -210.4% | ||
| Q4 22 | — | -192.5% |
| Q4 25 | — | — | ||
| Q3 25 | -263.7% | — | ||
| Q1 24 | — | -129.8% | ||
| Q4 23 | — | 76.2% | ||
| Q3 23 | — | -158.5% | ||
| Q2 23 | — | -197.8% | ||
| Q1 23 | — | -212.1% | ||
| Q4 22 | — | -192.6% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.15 | — | ||
| Q1 24 | — | $-0.33 | ||
| Q4 23 | — | $-0.56 | ||
| Q3 23 | — | $-0.65 | ||
| Q2 23 | — | $-0.90 | ||
| Q1 23 | — | $-0.81 | ||
| Q4 22 | — | $-0.70 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $333.3M | $177.6M |
| Total DebtLower is stronger | $14.4M | — |
| Stockholders' EquityBook value | $204.2M | $-228.1M |
| Total Assets | $498.0M | $365.9M |
| Debt / EquityLower = less leverage | 0.07× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $333.3M | — | ||
| Q3 25 | $113.9M | — | ||
| Q1 24 | — | $177.6M | ||
| Q4 23 | — | $203.5M | ||
| Q3 23 | — | $251.3M | ||
| Q2 23 | — | $335.7M | ||
| Q1 23 | — | $355.9M | ||
| Q4 22 | — | $422.0M |
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
| Q4 25 | $204.2M | — | ||
| Q3 25 | $74.1M | — | ||
| Q1 24 | — | $-228.1M | ||
| Q4 23 | — | $-204.2M | ||
| Q3 23 | — | $-157.2M | ||
| Q2 23 | — | $-102.3M | ||
| Q1 23 | — | $-48.9M | ||
| Q4 22 | — | $-21.4M |
| Q4 25 | $498.0M | — | ||
| Q3 25 | $225.9M | — | ||
| Q1 24 | — | $365.9M | ||
| Q4 23 | — | $423.5M | ||
| Q3 23 | — | $460.4M | ||
| Q2 23 | — | $515.1M | ||
| Q1 23 | — | $538.5M | ||
| Q4 22 | — | $610.1M |
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.8M | $-59.3M |
| Free Cash FlowOCF − Capex | $-47.4M | $-59.3M |
| FCF MarginFCF / Revenue | -284.7% | -233.9% |
| Capex IntensityCapex / Revenue | 57.9% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-274.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-37.8M | — | ||
| Q3 25 | $-8.9M | — | ||
| Q1 24 | — | $-59.3M | ||
| Q4 23 | — | $-18.3M | ||
| Q3 23 | — | $-84.5M | ||
| Q2 23 | — | $-110.6M | ||
| Q1 23 | — | $-101.6M | ||
| Q4 22 | — | $-52.5M |
| Q4 25 | $-47.4M | — | ||
| Q3 25 | $-12.0M | — | ||
| Q1 24 | — | $-59.3M | ||
| Q4 23 | — | $-18.6M | ||
| Q3 23 | — | $-85.2M | ||
| Q2 23 | — | $-111.6M | ||
| Q1 23 | — | $-102.2M | ||
| Q4 22 | — | $-52.8M |
| Q4 25 | -284.7% | — | ||
| Q3 25 | -245.5% | — | ||
| Q1 24 | — | -233.9% | ||
| Q4 23 | — | 25.2% | ||
| Q3 23 | — | -212.3% | ||
| Q2 23 | — | -251.7% | ||
| Q1 23 | — | -282.6% | ||
| Q4 22 | — | -153.8% |
| Q4 25 | 57.9% | — | ||
| Q3 25 | 64.4% | — | ||
| Q1 24 | — | 0.1% | ||
| Q4 23 | — | -0.3% | ||
| Q3 23 | — | 1.7% | ||
| Q2 23 | — | 2.2% | ||
| Q1 23 | — | 1.6% | ||
| Q4 22 | — | 1.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASPI
Segment breakdown not available.
KYNB
| Drug Product Revenue | $24.5M | 97% |
| Other | $878.0K | 3% |
